Rowland was previously President of Sirtex Medical US from 2002 to 2006.
His role with Oncosil will include being responsible for developing and executing the company's U.S. Business plan.
Rowland will be the company's official representative with the U.S. FDA as it works towards U.S. licensure for its lead product candidate, the OncoSil™ localised radiation treatment for cancer.
Daniel Kenny, CEO, commented:
"We are delighted to announce the appointment of Mr Charles Rowland as President of our USA operations.
"His is a key appointment as we move into a highly significant phase in the licensing & commercialisation of OncoSil™, in the US market."
How OncoSil™ works
OncoSil™ is an implantable nuclear medicine (radiotherapy) device that has been successfully piloted in pancreatic and liver cancer.
The device is inserted directly into the centre of the tumour using well established technology.
OncoSil™ has clinically demonstrated target tumour regression (tumour shrinkage) in both solid tumour indications of pancreatic and liver cancer.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.